[1]于　鹤,刘光新.新辅助化学治疗联合肿瘤细胞减灭术治疗晚期卵巢癌疗效观察[J].新乡医学院学报,2020,37(3):258-260.[doi:10.7683/xxyxyxb.2020.03.014]
　YU He,LIU Guangxin.Effect of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced ovarian cancer[J].Journal of Xinxiang Medical University,2020,37(3):258-260.[doi:10.7683/xxyxyxb.2020.03.014]
点击复制

新辅助化学治疗联合肿瘤细胞减灭术治疗晚期卵巢癌疗效观察
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
37
期数:
2020年3
页码:
258-260
栏目:
临床研究
出版日期:
2020-03-12

文章信息/Info

Title:
Effect of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced ovarian cancer
作者:
于　鹤; 刘光新
（周口市中心医院妇科，河南　周口　466000）
Author(s):
YU He; LIU Guangxin
(Department of Gynecology,Zhoukou Central Hospital,Zhoukou 466000,Henan Province,China)
关键词:
卵巢癌; 新辅助化疗; 肿瘤细胞减灭术
Keywords:
ovarian cancer; neoadjuvant chemotherapy; cytoreductive surgery
分类号:
R737.31
DOI:
10.7683/xxyxyxb.2020.03.014
文献标志码:
A
摘要:
目的　探讨新辅助化学治疗联合肿瘤细胞减灭术治疗晚期卵巢癌的临床效果。方法　选择2012年1月至2015年12月周口市中心医院妇科收治的87例Ⅲ、Ⅳ期上皮性卵巢癌患者为研究对象，根据治疗方案将患者分为观察组（n=43）和对照组（n=44）。对照组患者给予初始肿瘤细胞减灭术，观察组患者给予新辅助化学治疗联合肿瘤细胞减灭术，2组患者术后均给予铂类为基础的常规化学治疗。对2组患者手术时间、术中出血量、残留病灶大小、临床疗效、并发症发生率及术后1、2、3 a生存率进行比较。结果　观察组患者手术时间和术中出血量显著低于对照组（P<0.05）；2组患者术后住院时间比较差异无统计学意义（P>0.05）。观察组和对照组患者满意的肿瘤细胞减灭率分别为74.42%（32/43）、52.27%（23/44），观察组患者满意的肿瘤细胞减灭率显著高于对照组（χ2=4.587，P<0.05）。观察组和对照组患者并发症发生率分别为11.63%（5/43）、20.45%（9/44），2组患者并发症发生率比较差异无统计学意义（χ2=1.255，P>0.05）。观察组和对照组患者治疗有效率分别为79.07%（34/43）、50.00%（22/44），观察组患者治疗有效率显著高于对照组（χ2=9.725，P<0.05）。观察组患者术后1、2、3 a 生存率分别为95.35%（41/43）、81.40%（35/43）、 67.44%（29/43），对照组患者术后1、2、3 a 生存率分别为93.18%（41/44）、75.00%（33/44）、52.27%（23/44）；2组患者术后1、2、3 a生存率比较差异无统计学意义（P>0.05）。结论　新辅助化学治疗可以显著缩短晚期卵巢癌患者肿瘤细胞减灭术手术时间，减少术中出血量，提高满意的肿瘤细胞减灭率，改善临床缓解率，但对患者生存率改善不显著。
Abstract:
Objective　To investigate the effect of neoadjuvant chemotherapy combined with cytoreductive surgery in the treatment of advanced ovarian cancer.Methods　A total of 87 patients with stage Ⅲ and Ⅳ epithelial ovarian cancer admitted to Zhoukou Central Hospital from January 2012 to December 2015 were selected as research objects.The patients were divided into observation group (n=43) and control group (n=44) according to the treatment plan.The patients in the control group were given initial cytoreductive surgery,and the patients in the observation group were given neoadjuvant chemotherapy combined with cytoreductive surgery.All patients in the two groups were given conventional chemotherapy based on platinum drugs after operation.The operation time,intraoperative bleeding volume,residual focus size,clinical effect,complication rate and 1-,2-,3-year survival rate after operation were compared between the two groups.Results　The operation time and intraoperative bleeding volume in the observation group were significantly lower than those in the control group (P<0.05)；There was no significant difference in postoperative hospitalization time between the two groups (P>0.05).The rate of satisfactory cytoreductive surgery in the observation group and the control group was 74.42% (32/43) and 52.27% (23/44),respectively.The rate of satisfactory cytoreductive surgery in the observation group was significantly higher than that in the control group (χ2=4.587,P<0.05).The incidence of complications in the observation group and the control group was 11.63% (5/43) and 20.45% (9/44),respectively.There was no significant difference in the incidence of complications between the two groups (χ2=1.255,P>0.05).The effective rate in the observation group and the control group was 79.07% (34/43) and 50.00% (22/44),respectively.The effective rate in the observation group was significantly higher than that in the control group (χ2=9.725,P<0.05).The 1-,2- and 3-year survival rates in the observation group were 95.35% (41/43),81.40% (35/43) and 67.44% (29/43),respectively；and they were 93.18% (41/44),75.00% (33/44) and 52.27% (23/44) in the control group,respectively.There was no significant difference in 1-,2- and 3-year survival rates between the two groups (P>0.05).Conclusions　Neoadjuvant chemotherapy can significantly shorten the operation time of cytoreductive surgery in patients with advanced ovarian cancer,reduce the intraoperative bleeding volume,improve the rate of satisfactory cytoreductive surgery and clinical remission rate；but the improvement of survival rate is not significant.

参考文献/References:

［1］　TORRE L A,TRABERT B,DESANTIS C E,et al.Ovarian cancer statistics,2018［J］.CA Cancer J Clin,2018,68(4):284-296.
［2］　仝玉珠.腹腔镜下全面分期手术治疗早期卵巢癌疗效观察［J］.新乡医学院学报，2018，35（9）：804-806.
［3］　HEINTZ A P,ODICINO F,MAISONNEUVE P,et al.Carcinoma of the ovary.FIGO 26th annual report on the results of treatment in gynecological cancer［J］.Int J Gynaecol Obstet,2006,95(Suppl 1):S161-S192.
［4］　胡丹，王欣，张傢钧，等.新辅助化疗治疗晚期卵巢癌的研究进展［J］.国际生殖健康/计划生育杂志，2019，38（4）：349-352.
［5］　VERGOTE I,DU BOIS A,ARRANT F,et al.Neoadjuvant chemotherapy in advanced ovarian cancer:on what do we agree and disagree ［J］.Gynecol Oncol,2013,128(1):6-11.
［6］　RUSFIN G J,QUINN M,THIGPEN T,et al.New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) ［J］.J Natl Cancer Inst,2004,96(6):487-488.
［7］　吴昊，石杨杨，梅雅婷，等.新辅助化疗对晚期卵巢癌患者疗效及预后分析［J］.中国临床保健杂志，2019，22（2）：250-254.
［8］　李洋.腹腔镜手术治疗早期卵巢癌疗效观察［J］.新乡医学院学报，2019，36（2）：159-161.
［9］　段小霞.新辅助化疗后间歇性肿瘤细胞减灭术治疗晚期卵巢癌的临床效果［J］.临床医学研究与实践，2019，4（2）：8-9.
［10］　姚俊阁，岳青芬，李冰熠.新辅助化疗、肿瘤细胞减灭术、手术后化疗(腹腔热灌注)对晚期卵巢癌的疗效分析［J］.北方药学，2018，15（11）：42-43.

相似文献/References:

[1]图妮沙古丽·阿卜拉江,艾星子·艾里,丁岩,等.卵巢癌早期诊断相关因子研究进展[J].新乡医学院学报,,():000.
[2]袁源.血清糖链抗原125和人附睾分泌蛋白4联合检测在卵巢癌诊断中的价值[J].新乡医学院学报,2012,29(11):850.
[3]韩碧波,魏海东,郑　磊,等.经阴道彩色多普勒超声联合血清糖链抗原125和人附睾蛋白4水平检测对卵巢癌的诊断价值[J].新乡医学院学报,2019,36(10):971.[doi:10.7683/xxyxyxb.2019.10.016]
　HAN Bi-bo,WEI Hai-dong,ZHENG Lei,et al.Diagnostic value of transvaginal color Doppler sonography combined with serum carbohydrate antigen 125 and human epididymis protein 4 in ovarian cancer[J].Journal of Xinxiang Medical University,2019,36(3):971.[doi:10.7683/xxyxyxb.2019.10.016]
[4]路　娜,王炳淑,古吉敏.卵巢癌组织中带状疱疹透明带样结构域蛋白1 mRNA表达与肿瘤增殖、侵袭及自噬相关基因表达的相关性[J].新乡医学院学报,2019,36(10):958.[doi:10.7683/xxyxyxb.2019.10.013]
　LU Na,WANG Bing-shu,GU Ji-min.Correlation between the expression of CUB and zona pellucida-like domains-containing protein 1 mRNA and the expression of genes related to proliferation,invasion and autophagy in ovarian cancer tissues[J].Journal of Xinxiang Medical University,2019,36(3):958.[doi:10.7683/xxyxyxb.2019.10.013]
[5]陈志军,曹克鑫,甘绍印,等.胸腺肽α1联合顺铂和氟尿嘧啶新辅助化疗治疗食管癌疗效观察[J].新乡医学院学报,2021,38(3):268.[doi:10.7683/xxyxyxb.2021.03.013]
　CHEN Zhijun,CAO Kexin,GAN Shaoyin,et al.Therapeutic effect of thymosin α1 combined with cisplatin and fluorouracil neoadjuvant chemotherapy on esophageal cancer[J].Journal of Xinxiang Medical University,2021,38(3):268.[doi:10.7683/xxyxyxb.2021.03.013]
[6]王黎伟,王志芬,孔丽茹,等.超声造影联合血清基质细胞衍生因子-1和磷酸化应激诱导蛋白1检测对卵巢癌的诊断价值[J].新乡医学院学报,2021,38(5):481.[doi:10.7683/xxyxyxb.2021.05.018]
　WANG Liwei,WANG Zhifen,KONG Liru,et al.Diagnostic value of contrast-enhanced ultrasound combined with serum stromal cell-derived factor-1 and stress-induced phosphoprotein 1 for ovarian cancer[J].Journal of Xinxiang Medical University,2021,38(3):481.[doi:10.7683/xxyxyxb.2021.05.018]
[7]张镛镛,王　芳,雷利娜,等.血清高迁移率族蛋白A2、糖链抗原19-9联合ROMA指数对卵巢癌的诊断价值[J].新乡医学院学报,2020,37(5):471.[doi:10.7683/xxyxyxb.2020.05.17]
　ZHANG Yongyong,WANG Fang,LEI Lina,et al.Diagnostic value of serum high mobility group protein A2,carbohydrate antigen 19-9 and ROMA index in ovarian cancer[J].Journal of Xinxiang Medical University,2020,37(3):471.[doi:10.7683/xxyxyxb.2020.05.17]
[8]豆秋彦,冯　文,李春霖.脂肪因子chemerin在女性常见恶性肿瘤中的作用研究进展[J].新乡医学院学报,2020,37(12):1195.[doi:10.7683/xxyxyxb.2020.12.021]
[9]仝玉珠.腹腔镜下全面分期手术治疗早期卵巢癌疗效观察[J].新乡医学院学报,2018,35(9):804.[doi:10.7683/xxyxyxb.2018.09.013]
　TONG Yu-zhu.Clinical effect of laparoscopic radical staged surgery in the treatment of early ovarian cancer[J].Journal of Xinxiang Medical University,2018,35(3):804.[doi:10.7683/xxyxyxb.2018.09.013]
[10]何社红,薛聪玲.谷胱甘肽转移酶-π与卵巢癌多药耐药的关系[J].新乡医学院学报,2017,34(4):320.[doi:10.7683/xxyxyxb.2017.04.020]
　HE She-hong,XUE Cong-ling.Relationship between glutathione S-transferase-π and multidrug resistance of ovarian cancer[J].Journal of Xinxiang Medical University,2017,34(3):320.[doi:10.7683/xxyxyxb.2017.04.020]

更新日期/Last Update: 2020-03-05